DNA graphic

Funding Opportunities

The Lupus Research Alliance seeks to fund biomedical research that will discover better diagnostics, improve medical treatments and advance translational and clinical research that will ultimately lead to a cure for lupus. Our grant funding opportunities provide distinct opportunities for researchers to test their most innovative hypothesis by applying cutting edge methodologies to further investigation in the lupus and autoimmune space.

The LRA-Celgene Accelerator Awards provide up to $150,000 per year for up to two years. The awards aim to fund cutting-edge research projects that focus on understanding the underlying mechanism of disease, addressing lupus heterogeneity, and identifying novel biomarkers. The program’s objective is to stimulate lupus research innovation, accelerate investigation on human lupus rather than relevant model organisms, and realize synergies between academia and industry.

Examples of pertinent topics include, but are not limited to:

  • Mechanism of disease: Mining of bulk and single-cell transcriptomic and proteomic datasets derived from lupus patient blood and target tissues (e.g., skin, joint, kidney);
  • Target discovery and validation: Characterization of genetic drivers of lupus, such as but not limited to understanding gain-of-function or loss-of-function risk alleles, eQTLS, or mRNA splicing;
  • Biomarker identification: Identify or validate early biomarkers of clinical flares, remission or response to therapy;
  • Patient selection: Novel methods of identifying SLE patient subsets based on immunological and clinical heterogeneity;
  • Clinical endpoint derivation and harmonization: addressing the need for outcome measures for skin disease, lupus-specific arthritis measures, and other endpoints that would facilitate and accelerate the conduct of clinical trials in lupus and its complications.

A two-stage application process will be employed. A 2-page Letter of Intent (LOI) will be used to judge the significance, novelty, and alignment of the proposed project concept with the LRA-Celgene Accelerator Award. LOIs must be submitted electronically via proposalCENTRAL.com by 11:59 pm ET on October 25, 2019. Only applicants whose LOIs have successfully passed this first review stage will be invited to submit full applications.

Click here for the Request for Applications.

Please send any scientific inquiries to:
Dr. Teodora Staeva, Chief Scientific Officer at tstaeva@lupusresearch.org;

All administrative inquiries should be sent to:
Diomaris Gonzalez, Director, Grant Programs at dgonzalez@lupusresearch.org.

The Distinguished Innovator Award grant mechanism is intended to attract exceptionally creative scientists from all relevant scientific disciplines and to provide them with a robust and sustained support to explore bold and paradigm shifting ideas that could lead to ground-breaking discoveries in lupus research. Research conducted under this grant mechanism is expected to be highly innovative and to address the fundamental causes of systemic lupus erythematosus that can provide new directions towards a cure.

Please send any scientific inquiries to Dr. Teodora Staeva, Chief Scientific Officer at tstaeva@lupusresearch.org; all administrative inquiries should be sent to Diomaris Gonzalez, Director, Grant Programs at dgonzalez@lupusresearch.org.

Currently, we are not accepting any applications for this grant mechanism. However, we encourage you to contact us if you are interested in receiving future requests for proposals.

Target Identification in Lupus (TIL): up to $200,000/year total costs for up to 3 years.

Supports highly meritorious research focused on the identification and scientific and/or clinical investigation of molecular pathways and therapeutic targets that will lead to new therapies or improved management for patients with lupus.

Please send any scientific inquiries to Dr. Teodora Staeva, Chief Scientific Officer at tstaeva@lupusresearch.org; all administrative inquiries should be sent to Diomaris Gonzalez, Director, Grant Programs at dgonzalez@lupusresearch.org.

Please note that while the Target Identification in Lupus and the Novel Research Grants funding mechanisms follow the same review timeline, they have distinct objectives, application templates, and selection criteria. The same research project may not be submitted for consideration to both grant mechanisms.  Such submissions will be triaged without review.

Currently, we are not accepting any applications for this grant mechanism. However, we encourage you to contact us if you are interested in receiving future requests for proposals.

Novel Research Grants (NRG): up to $150,000/year total costs for up to 2 years.

They provide early stage support for highly innovative approaches to major challenges in lupus research. Special emphasis is placed on lupus studies exploring fundamental mechanisms, novel targets and pathways, novel technologies, and interdisciplinary approaches. Early-career investigators are encouraged to apply through this mechanism.

Please send any scientific inquiries to Dr. Teodora Staeva, Chief Scientific Officer at tstaeva@lupusresearch.org; all administrative inquiries should be sent to Diomaris Gonzalez, Director, Grant Programs at dgonzalez@lupusresearch.org.

Please note that while the Novel Research Grants and the Target Identification in Lupus funding mechanisms follow the same review timeline, they have distinct objectives, application templates, and selection criteria. The same research project may not be submitted for consideration to both grant mechanisms.  Such submissions will be triaged without review.

Currently, we are not accepting any applications for this grant mechanism. However, we encourage you to contact us if you are interested in receiving future requests for proposals.

Learn and connect with our community!